Endoscopic Versus Open Resection for Small Gastric Gastrointestinal Stromal Tumors

Safety and Outcomes

Chaoyong Shen, MD, Haining Chen, MD, Yuan Yin, MD, Jiaju Chen, MD, Luyin Han, BN, Bo Zhang, PhD, Zhixin Chen, PhD, and Jiaping Chen, PhD

Abstract: Endoscopic resection has been performed to treat small gastric neoplasms. However, this technique for small gastric gastrointestinal stromal tumors (GISTs) remains controversial. This study aims to compare the safety and surgical outcomes of endoscopic versus open resection of small gastric GISTs.

The medical records of 54 consecutive gastric GISTs patients with tumor size of \( \leq 2 \) cm, who were surgically treated with endoscopic resection (endoscopic group) or open surgery (laparotomy group) in a single institution from March 2010 to June 2014, were retrospectively analyzed. The clinical and tumor characteristics, surgical safety, and tumor-related outcomes were evaluated.

Of 54 patients, 32 and 22 patients underwent endoscopic resection and laparotomy, respectively. Patients who underwent endoscopic resection yielded a significantly shorter hospital stay compared with patients who underwent laparotomy (\( P < 0.001 \)). Compared with patients in the endoscopic group, patients in the laparotomy group had more intraoperative blood loss (\( P < 0.001 \)), longer nasogastric tube retention (\( P < 0.001 \)), and required longer operative time (\( P < 0.001 \)). More laparotomy patients required postoperative analgesic drugs than those in the endoscopic group (\( n = 9 \) vs \( 4 \); \( P = 0.016 \)). Gastric perforation occurred in 1 case during operation in the endoscopic group. Patients who underwent these 2 procedures did not differ with respect to tumor size (\( P = 0.168 \)), perioperative transfusion (\( P = 1.000 \)), reoperation (\( P = 1.000 \)), early satiety (\( P = 0.560 \)), and postoperative bleeding (\( P = 1.000 \)). With a median follow-up time of 34.5 months, 1 high-risk patient in each group experienced tumor recurrence/metastasis postoperatively.

The endoscopic procedure allows safe resection with good surgical outcomes for small gastric GISTs compared with laparotomy. Moreover, larger randomized controlled trials are warranted to confirm endoscopic application for small gastric GISTs.

(Medicine 94(1):e376)

GISTs = gastrointestinal stromal tumors, NIH = National Institutes of Health.

INTRODUCTION

Gastrointestinal stromal tumors (GISTs), which originate from the interstitial cells of Cajal or its precursor, may be asymptomatic and nonmalignant when diagnosed but have a potential for malignant transformation.\(^2\) Currently, the therapeutic guideline of small GISTs as identified by endoscopic ultrasonography (EUS) remains uncertain. Some small masses gradually grow, may have symptoms, and finally undergo malignant transformation.\(^3\) Thus, surgical treatment becomes necessary. Macroscopically and histologically negative surgical margins and avoidance of tumor rupture are the principles of surgical treatment.\(^5\) However, previous reports have shown that recurrence of GISTs was primarily dependent on tumor biology rather than microscopic margins.\(^6\) Thus, various types of surgical procedures, such as traditional open surgery, laparoscopic and endoscopic resection, have been performed for GISTs.

To date, several publications have reported endoscopic resection techniques, including endoscopic submucosal dissection (ESD), submucosal tunneling endoscopic resection, and ligature-assisted endoscopic enucleation.\(^10\)\(^11\) Findings from recent reports have demonstrated that in patients with GISTs, even in tumors with a maximum size of up to 5 cm, endoscopic resection is safe and feasible.\(^12\) Theoretically, endoscopic resection is simple and feasible for some tumors, but the risk of early tumor recurrence caused by incomplete excision has become a major concern for surgeons. By contrast, open surgery, which can remove the entire tumor with a histologically negative margin, is widely recognized as the most effective procedure to treat malignant tumors from both technical and oncologic points of view. However, to the best of our knowledge, although previous case series have reported endoscopic resection for GISTs, the safety and surgical outcomes between endoscopic and open resection of GISTs have not yet been reported. We, therefore, set out to assess the outcomes of endoscopic resection in comparison to the traditional abdominal surgical approach for the treatment of small gastric GISTs.

MATERIALS AND METHODS

Patient Selection

Patients with gastric stromal tumors who were not randomly treated with endoscopic resection or laparotomy in a single medical institution (West China Hospital, Sichuan University, Sichuan, China) between March 2010 and June 2014 were reviewed. Operation consents were obtained from each patient in this cohort. However, the institutional review board...
and committee of the West China Hospital of Sichuan University deemed that the approval of the committee was not required for the retrospective analysis of clinical data. The following patients were included in the study: patients with tumor diameter not larger than 2 cm based on preoperative EUS and/or abdominal computerized tomography (CT) examination; patients who had not taken aspirin, warfarin, or other nonsteroidal anti-inflammatory drug for at least 1 week before the endoscopic resection; patients who had normal complete blood count, prothrombin time, and thrombin time; patients with no other malignant tumors; and patients who were pathologically diagnosed as having GISTs preoperatively or postoperatively. Patients who refused surgical intervention were excluded. The surgical approaches were decided according to the tumor growth pattern, EUS findings, or patients’ preference.

**Surgical Procedures and Management**

All patients received general anesthesia. The surgical procedures included ESD (endoscopic group) and open resection (laparotomy group). Endoscopic resection was mainly chosen for patients with tumors originating from the muscularis propria or tumors with intragastric type (Figure 1A–D) and clear boundaries to adjacent tissues and organs. All endoscopic resections were performed by skilled endoscopic specialists and surgeons. For patients in the endoscopic group, EUS was again performed to determine the tumor size, layer of origin, and tumor growth pattern before the procedure. A hook knife, insulated-tip knife, needle knife, grasping forceps, and titanium clips were used to dissect the tumor. First, we submucosally injected methylene blue-stained saline, including epinephrine (1:100,000), to lift the lesion off the muscle layer. A hook knife or insulated-tip knife was used to cut the mucosal surface and dissect the tumor. Electrocautery snare and norepinephrine were used in some cases to reduce bleeding. The wound was closed with titanium clips, and medical adhesive was used for some patients to immobilize clips and healing wounds (Figure 2A and B). Nasogastric tube was routinely retained after the procedure. Endoscopic complete resection of tumors is regarded as the absence of residual tumor tissue macroscopically on endoscopy (Figure 2C) and microscopically. All patients received proton-pump inhibitors, and endoscopic examinations were performed postoperatively. For patients in the laparotomy group, the procedure started with a traditional midline upper abdominal incision. Frozen slices of the incisal margin and tumor were routinely collected during surgery. The operation was regarded as completed once the surgical margins were

![FIGURE 1.](image-url) (A and B) Images of lesions located in the muscularis propria of the middle part of the stomach with a fairly clear boundary, as confirmed by EUS. (C and D) Endoscopic view of tumors located in the gastric body and tumors growing with an intragastric-type pattern. EUS = endoscopic ultrasonography.
confirmed to be negative. Patients with diabetes were insulinized preoperatively and medications were adjusted to rational control hypertension. A soft diet was allowed for patients with ESD who were free from perforation or endoscopic bleeding, and food was allowed for laparotomy patients after removal of gastrointestinal decompression.

Data Collection and Postoperative Follow-Up

The parameters measured that were retrospectively reviewed from their medical records included demographic and clinicopathological characteristics, surgical data (procedures, intraoperative findings, operative times, and complications), morbidity, mortality, and duration of hospital stay. Follow-up was regularly conducted through office visit, telephone, or outpatient clinic visit from July 2014 to August 2014. During the follow-up, data collection included surgical complications, postoperative adjuvant therapy with imatinib mesylate (Glivec/Gleevec; Novartis Pharma AG, Basel, Switzerland), tumor recurrence/metastasis, and death. EUS and abdominal CT scanning were used every 6 to 12 months postoperatively.

Statistical Analysis

Median values were used to describe continuous data. Quantitative results were expressed as mean ± standard deviation. Categorical data from different groups were compared using the \( \chi^2 \) test or Fisher exact test. Wilcoxon test was used to test ranked data. Differences between the 2 groups were compared using an independent sample \( t \) test. All data analyses were performed using SPSS version 17.0 (SPSS, Chicago, IL) statistical software package for Microsoft Windows. \( P \) values of <0.05 were considered to be statistically significant.

RESULTS

Demographic Data and Clinical Characteristics

Table 1 summarizes the clinical and demographic features between 2 surgical approaches. All 54 patients with small gastric GISTs underwent endoscopic resection or surgical resection through the abdominal approach, and 15 patients were diagnosed with GIST preoperatively. The endoscopic group (n = 32) was composed of 15 males (46.9%) and 17 females (53.1%) and had a median age of 61 years (range, 37–81 years). Accordingly, the laparotomy group was composed of 11 males (50.0%) and 11 females (53.1%).
females (50.0%), with a median age of 55 years (range, 37–73 years). The most common clinical symptom was abdominal pain or discomfort, followed by alimentary tract bleeding. Patients in the endoscopic group had a significantly shorter hospital stay than the patients in the laparotomy group (5.34 ± 2.34 vs 13.68 ± 3.52 days; \( P < 0.001 \)). The gender, age, and history of diabetes or hypertension did not differ between either of the groups.

### Tumor Characteristics

A total of 30 masses were located in the cardia or fundus, 20 in the body, and 4 in the antrum. The endoscopic group had a higher proportion of tumors located in the cardia/fundus compared with that of the laparotomy group (\( P = 0.012 \)). A significant difference was observed in the growth patterns between the 2 groups (\( P < 0.001 \)). According to the modified National Institutes of Health (NIH) risk categories,13 in the endoscopic group, 9 tumors were of very low risk, 18 were of low risk, 3 were of intermediate risk, and 2 were of high risk. In the laparotomy group, 3 tumors were of very low risk, 13 were of low risk, 4 were of intermediate risk, and 2 were of high risk. A total of 5 patients with intermediate/high risk were treated with imatinib mesylate (400 mg/d). No significant differences were found between the endoscopic and the laparotomy group with respect to mitotic count (\( P = 0.316 \)), NIH risk classification (\( P = 0.324 \)), tumor size (\( P = 0.168 \)), and immunohistochemical characteristics (\( P > 0.05 \)).

### Surgical Information

None of the patients underwent total or subtotal gastrectomy. Open surgery with local resection was performed in all cases.

#### TABLE 1. Clinicopathologic and Demographic Features for Gastric Gastrointestinal Stromal Tumors Between 2 Surgical Approaches

| Parameters                        | Endoscopic Group (n = 32) | Laparotomy Group (n = 22) | \( P \) Value |
|-----------------------------------|---------------------------|---------------------------|--------------|
| Age, y                            |                           |                           | 0.319        |
| Median                            | 61                        | 55                        |              |
| Range                             | 37–81                     | 37–73                     |              |
| Gender (%)                        |                           |                           | 0.821        |
| Male                              | 15 (46.9)                 | 11 (50.0)                 |              |
| Female                            | 17 (53.1)                 | 11 (50.0)                 |              |
| Main clinical presentations (%)   |                           |                           | 1.000        |
| Alimentary tract bleeding         | 8 (25.0)                  | 5 (22.7)                  |              |
| Abdominal pain or discomfort      | 21 (65.6)                 | 15 (68.2)                 |              |
| Incidentally found                | 3 (9.4)                   | 2 (9.1)                   |              |
| Follow-up, mo                     |                           |                           | 0.275        |
| Median                            | 31.5                      | 38.5                      |              |
| Range                             | 2–53                      | 5–50                      |              |
| Tumor location (%)                |                           |                           | 0.012        |
| Cardia/fundus                     | 21 (65.6)                 | 9 (40.9)                  |              |
| Body                              | 7 (21.9)                  | 13 (59.1)                 |              |
| Antrum                            | 4 (12.5)                  | 0 (0.0)                   |              |
| Tumor size, cm; mean ± SD         | 1.70 ± 0.36               | 1.82 ± 0.20               | 0.168        |
| Growth pattern (%)                |                           |                           | <0.001       |
| Intragastric                      | 32 (100.0)                | 6 (27.3)                  |              |
| Extragastric/mixed                | 0 (0.0)                   | 16 (72.7)                 |              |
| Hospital stay, d; mean ± SD       | 5.34 ± 2.34               | 13.68 ± 3.52              | <0.001       |
| History of diabetes (%)           | 1 (3.1)                   | 2 (9.1)                   | 0.560        |
| History of hypertension (%)       | 4 (12.5)                  | 3 (13.6)                  | 1.000        |
| Combined with peptic ulcer (%)    | 2 (6.3)                   | 0 (0.0)                   | 0.525        |
| Mitotic index (%)                 |                           |                           | 0.316        |
| \( \leq 5/50 \text{HPF} \)        | 27 (84.4)                 | 16 (72.7)                 |              |
| \( 6–10/50 \text{HPF} \)          | 3 (9.4)                   | 4 (18.2)                  |              |
| \( >10/50 \text{HPF} \)           | 2 (6.3)                   | 2 (9.1)                   |              |
| NIH risk classification (%)       |                           |                           | 0.324        |
| Very low and low                  | 27 (84.4)                 | 16 (72.7)                 |              |
| Intermediate and high             | 5 (15.6)                  | 6 (27.3)                  |              |
| CD117 positive (%)                | 30 (93.8)                 | 21 (95.5)                 | 1.000        |
| CD34 positive (%)                 | 31 (96.9)                 | 21 (95.5)                 | 1.000        |
| Dog-1 positive (%)                | 29 (90.6)                 | 22 (100.0)                | 0.262        |
| S-100 positive (%)                | 0 (0.0)                   | 1 (4.5)                   | 0.407        |
| SMA positive (%)                  | 8 (25.0)                  | 1 (4.5)                   | 0.067        |
| Desmin positive (%)               | 4 (12.5)                  | 3 (13.6)                  | 1.000        |

CD34 = CD34 protein, CD117 = CD117 protein, Dog-1 = Dog-1 protein, HPF = high-power field, NIH = National Institutes of Health, S-100 = S-100 protein, SD = standard deviation, SMA = smooth muscle actin.
Parameters | Endoscopic Group (n = 32) | Laparotomy Group (n = 22) | P Value
--- | --- | --- | ---
Intraoperative bleeding, mL; mean ± SD | 7.38 ± 4.25 | 24.09 ± 6.38 | <0.001
Nasogastric tube retention, d; mean ± SD | 2.16 ± 0.92 | 4.32 ± 1.76 | <0.001
Operative time, min; mean ± SD | 31.34 ± 10.24 | 56.36 ± 11.97 | <0.001
Perioperative transfusion (%) | 1 (3.1) | 0 (0.0) | 1.000
Operation-related death (%) | 0 (0.0) | 0 (0.0) | —
Reoperation (%) | 1 (3.1) | 0 (0.0) | 1.000
Positive margins (%) | 0 (0.0) | 0 (0.0) | —
Postoperative bleeding (%) | 2 (6.3) | 1 (4.5) | 1.000
Perforation (%) | 1 (3.1) | 0 (0.0) | 1.000
Abdominal/wound infection (%) | 0 (0.0) | 0 (0.0) | —
Abdominal/incision pain (%) | 4 (12.5) | 9 (72.7) | 0.016
Pneumonia (%) | 0 (0.0) | 0 (0.0) | —
Intestinal obstruction (%) | 0 (0.0) | 0 (0.0) | —
Early satiety (%) | 1 (3.1) | 2 (9.1) | 0.560
Vomiting/nausea (%) | 1 (3.1) | 0 (0.0) | 1.000
Dysphagia (%) | 0 (0.0) | 0 (0.0) | —
Reflux symptoms (%) | 1 (3.1) | 0 (0.0) | 1.000
Tumor recurrence (%) | 1 (3.1) | 1 (4.5) | 1.000
Postoperative adjuvant therapy (%) | 2 (6.3) | 3 (13.6) | 0.388

SD = standard deviation.
devices and techniques, minimally invasive surgical resection including endoscopic, laparoscopic, and combined techniques has been performed widely in the treatment of gastric GISTs.\textsuperscript{12,20} Compared with open surgery, laparoscopic resection for gastric GISTs has been proven to be feasible and safe, whereas its application to small tumors is limited, especially in tumors <10 mm.\textsuperscript{12,22} Endoscopic resection has more advantages for elderly patients or patients with small-sized tumors; however, it remains controversial because of major complications, such as significant bleeding and perforation. Furthermore, the inherent risk of tumor spillage and positive microscopic margins is a huge concern.\textsuperscript{23} As such, long-term or even lifelong follow-up is needed if the tumor was removed by using a minimally invasive procedure. By contrast, open surgery can remove the entire lesion as well as a part of the normal tissue, which can provide a firmly negative surgical margin. However, an increasing number of studies have recently demonstrated that endoscopic resection can be safely performed with acceptable postoperative complications in selected cases.\textsuperscript{10,12,24} Given that many unanswered questions and equivocal evidence remain concerning the role of endoscopic resection for small gastric GISTs, we conducted this study to assess the feasibility of the endoscopic procedure.

Our series of patients who underwent endoscopic or laparotomy resection of gastric GISTs did not differ with respect to age, gender, tumor size, mitotic index, and clinicopathologic characteristics. However, patients with endoscopic resection had a higher proportion of tumors located in the cardia/fundus. As previously reported, endoscopic resection is less invasive than laparoscopic or open surgical interventions. However, the quick recovery, short postoperative hospitalization, and reduced amount of intraoperative bleeding for endoscopic procedure were noted.\textsuperscript{11,12} The procedure time, nasogastric tube retention time, and intraoperative bleeding were significantly lower in the endoscopic resection than in the laparoscopic intervention in this cohort. Generally, perforation cannot be avoided during the resection, even if performed by an experienced specialist,\textsuperscript{5,12,25,26} especially for GISTs tightly adherent to the muscularis propria or tumors with extragastic growth. In this series, 1 patient who underwent endoscopy experienced a perforation; however, the patient did not suffer from severe peritoneal cavity inflammation. Finally, gastric perforation was effectively repaired by laparoscopic procedure. Bleeding is also a common complication after surgery; nevertheless, severe postoperative bleeding sometimes needs reoperation. Our data showed that bleeding occurred in 2 patients in the endoscopic group and in 1 patient in the laparotomy group; however, all these patients were relieved after conservative medical therapy. Small GISTs normally do not recur after surgical removal of the tumors.\textsuperscript{9,10,24} The follow-up results from the 2 groups were comparable. With a median follow-up of 34.5 in this cohort, 2 patients with high risk in each group were found to have tumor recurrence or liver metastasis based on EUS examination or abdominal CT scans. No patients died because of GISTs according to our observations, although 1 patient in the endoscopic group died of respiratory failure. Of note, patients in the laparotomy group suffered from more pain compared with patients in the endoscopic resection group. Open surgery needs longer operation time and undergoes more invasive procedure compared with other procedures.

Perforation and bleeding may occur after endoscopic resection; thus, several measures were applied for wound closure of GISTs. Hemoclips, which were developed by Japanese scholars, have been used to manage various types of perforations and fistulas\textsuperscript{11,27} and can also effectively prevent bleeding. Tissue adhesives were frequently used during endoscopic resection, including fibrin sealant, cyanoacrylates, and thrombin.\textsuperscript{28,29} Cyanoacrylates have primarily been used in the treatment of bleeding from gastric varices with excellent results, and fibrin sealant is usually utilized for the closure of gastrointestinal fistula. Within the limitations of an observational and limited number of patients, our study has shown that endoscopic resection of gastric GISTs should be limited in selected cases. Long-term follow-up should be performed to assess the safety and effectiveness of endoscopic resection of GISTs. Therefore, our findings should be verified by multicenter and randomized controlled trials in the future.

In conclusion, few studies have compared the endoscopic and open approaches for small GISTs. Endoscopic procedure allows for safe resection with good surgical outcomes for small GISTs, although it cannot totally avoid perforations and bleeding during the procedure.

**ACKNOWLEDGMENTS**

The authors gratefully acknowledge the staffs of the Department of Gastrointestinal Surgery and Gastroenterology, West China Hospital, Sichuan, China, who generously provided assistance in the collection of data throughout the duration of the study.

**REFERENCES**

1. Cassier PA, Ducimetière F, Lurkin A, et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer. 2010;103:165–170.

2. Kirsch R, Gao ZH, Riddell R. Gastrointestinal stromal tumors: diagnostic challenges and practical approach to differential diagnosis. Adv Anat Pathol. 2007;14:261–285.

3. Miettinen M, Lasota J. Gastrointestinal stromal tumor. Gastroenterol Clin North Am. 2013;42:399–415.

4. Rubin BP. Gastrointestinal stromal tumors: an update. Histopathology. 2006;48:83–96.

5. De Vogelaere K, Van De Winkel N, Aerts M, et al. Surgical management of gastrointestinal stromal tumours: a single centre experience during the past 17 years. Acta Chir Belg. 2014;114:167–173.

6. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–58.

7. Bialek A, Wiechowska-Kozlowska A, Huk J. Endoscopic submucosal dissection of large gastric stromal tumor arising from muscularis propria. Clin Gastroenterol Hepatol. 2010;8:e119–e120.

8. Hwang JC, Kim JH, Kim JH, et al. Endoscopic resection for the treatment of gastric subepithelial tumors originated from the muscularis propria layer. Hepatogastroenterology. 2009;56:1281–1286.

9. Ge N, Sun S, Wang S, et al. Endoscopic ultrasound-assisted tunnel-type endoscopic submucosal dissection for the treatment of esophageal tumors arising in the muscularis propria (with video). Endosc Ultrasound. 2013;2:11–15.

10. Guo J, Liu Z, Sun S, et al. Ligation-assisted endoscopic enucleation for the diagnosis and resection of small gastrointestinal tumors originating from the muscularis propria: a preliminary study. BMC Gastroenterol. 2013;13:88.
11. Nan G, Siyu S, Sheng W, et al. The role of hemoclips reinforcement in the ligation assisted endoscopic enucleation for small GISTs in gastric fundus. *Biomed Res Int.* 2014;2014:247602.

12. Jeong IH, Kim JH, Lee SR, et al. Minimally invasive treatment of gastric gastrointestinal stromal tumors: laparoscopic and endoscopic approach. *Surg Laparosc Endosc Percutan Tech.* 2012;22:244–250.

13. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. *Hum Pathol.* 2008;39:1411–1419.

14. Lv M, Wu C, Zheng Y, et al. Incidence and survival analysis of gastrointestinal stromal tumors in Shanghai: a population-based study from 2001 to 2010. *Gastroenterol Res Pract.* 2010;2014:834136.

15. Goh BK, Chow PK, Yap WM, et al. Which is the optimal risk stratification system for surgically treatment localized primary GIST? Comparison of three contemporary prognosis criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. *Ann Surg Oncol.* 2008;15:2153–2163.

16. Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. *Lancet Oncol.* 2012;13:265–274.

17. Miettinen M, Lasota J. Gastrointestinal stromal tumors. Review on morphology, molecular pathology, prognosis, and differential diagnosis. *Arch Pathol Lab Med.* 2006;130:1466–1478.

18. Guo J, Liu Z, Sun S, et al. Endosonography-assisted diagnosis and therapy of gastrointestinal submucosal tumors. *Endoscopic Ultrasound.* 2013;2:125–133.

19. Blay JY, Von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. *Cancer.* 2010;116:5126–5137.

20. Dholakia C, Gould J. Minimally invasive resection of gastrointestinal stromal tumors. *Surg Clin North Am.* 2008;88:1009–1018.

21. Matthews BD, Walsh RM, Kercher KW, et al. Laparoscopic vs open resection of gastric stromal tumors. *Surg Endosc.* 2002;16:803–807.

22. De Vogelaere K, Hooeens A, Haentjens P, et al. Laparoscopic versus open resection of gastrointestinal stromal tumors of the stomach. *Surg Endosc.* 2013;27:1546–1554.

23. Davila RE, Faigel DO. GI stromal tumors. *Gastrointest Endosc.* 2003:58:80–88.

24. Huang WH, Feng CL, Lai HC, et al. Endoscopic ligation and resection for the treatment of small EUS-suspected gastric GI stromal tumors. *Gastrointest Endosc.* 2010;71:1076–1081.

25. Jeong ID, Jung SW, Bang SJ, et al. Endoscopic enucleation for gastric subepithelial tumors originating in the muscularis propria layer. *Surg Endosc.* 2011;25:468–474.

26. Park YS, Park SW, Kim TI, et al. Endoscopic enucleation of upper-GI submucosal tumors by using an insulated-tip electrosurgical knife. *Gastrointest Endosc.* 2004;59:409–415.

27. Jensen DM, Machicado GA. Hemoclipping of chronic canine ulcers: a randomized, prospective study of initial deployment success, clip retention rates, and ulcer healing. *Gastrointest Endosc.* 2009;70:969–975.

28. Bhat YM. Tissue adhesives for endoscopic use. *Gastroenterol Hepatol.* 2014;10:251–253.

29. Wang S. Observation of wound-closure outcomes using tissue adhesive plus metal clip after endoscopic upper gastrointestinal muscularis propria tumor resection. *Am J Gastroenterol.* 2013;108:623–624.